NEUCYTE Trademark

Trademark Overview

On Wednesday, August 3, 2016, a trademark application was filed for NEUCYTE with the United States Patent and Trademark Office. The USPTO has given the NEUCYTE trademark a serial number of 87126215. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Wednesday, March 6, 2024. This trademark is owned by Neucyte, Inc.. The NEUCYTE trademark is filed in the Chemical Products category with the following description:

Cells for medical and clinical research for the development of pharmaceutical products
neucyte

General Information

Serial Number87126215
Word MarkNEUCYTE
Filing DateWednesday, August 3, 2016
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateWednesday, March 6, 2024
Registration Number5318215
Registration DateTuesday, October 24, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 21, 2017

Trademark Statements

Goods and ServicesCells for medical and clinical research for the development of pharmaceutical products

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, January 12, 2017
Primary Code001
First Use Anywhere DateWednesday, May 31, 2017
First Use In Commerce DateWednesday, May 31, 2017

Trademark Owner History

Party NameNeucyte, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMountain View, CA 94043
Party NameNeucyte, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPalo Alto, CA 94306
Party NameNeucyte, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPalo Alto, CA 94306

Trademark Events

Event DateEvent Description
Wednesday, March 6, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Wednesday, March 6, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, March 6, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, September 14, 2023TEAS SECTION 8 & 15 RECEIVED
Monday, October 24, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, October 24, 2017REGISTERED-PRINCIPAL REGISTER
Thursday, September 21, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, September 20, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, September 5, 2017STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 15, 2017USE AMENDMENT FILED
Saturday, September 2, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 15, 2017TEAS STATEMENT OF USE RECEIVED
Wednesday, August 16, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 14, 2017SOU EXTENSION 1 GRANTED
Monday, August 14, 2017SOU EXTENSION 1 FILED
Monday, August 14, 2017SOU TEAS EXTENSION RECEIVED
Tuesday, April 18, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 21, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 21, 2017PUBLISHED FOR OPPOSITION
Wednesday, February 1, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 13, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 12, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 11, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 11, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 15, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 15, 2016NON-FINAL ACTION E-MAILED
Tuesday, November 15, 2016NON-FINAL ACTION WRITTEN
Monday, November 14, 2016ASSIGNED TO EXAMINER
Monday, August 8, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 6, 2016NEW APPLICATION ENTERED

Related Keywords

neucyte pharmaceutical products development research medical clinical cells